Direct oral anticoagulant therapies, including direct anti-Xa and thrombin inhibitors have
recently been introduced and may have advantages over vitamin K antagonists such as …

Protein C (PC) deficiency is a heritable or acquired risk factor for thrombophilia, with
presentations varying from asymptomatic to venous thromboembolism to neonatal purpura …

The article discusses a guideline from the British Committee for Standards in Haematology,
focusing on the non-coumarin anticoagulants and its effect on haemostasis. It states that the …

Factor V Leiden (FVLeiden) is a common hereditary thrombophilia that causes activated
protein C (APC) resistance. This review describes many of the most fascinating features of …

Severe inherited thrombophilia includes rare deficiencies of natural anticoagulants
(antithrombin and proteins C and S) and homozygous or combined factor V Leiden and FII …

The first direct oral anticoagulant (DOAC) to be approved for clinical use was dabigatran, a
direct thrombin inhibitor, in 2010. Since that time, four additional DOACs, all direct anti‐Xa …

Background: In recent years, several selectively acting anticoagulants, including the direct
thrombin inhibitors (DTI; argatroban, dabigatran) and the factor Xa inhibitors (rivaroxaban …

Oral vitamin K anticoagulation (warfarin, Coumadin, coumarin) has long been used for long-
term treatment and prophylaxis in a variety of clinical settings. Given the unpredictable …

Although direct oral anticoagulants (DOAC) do not require dose-adjustment on the basis of
laboratory test results, the measurement of their anticoagulant effect is useful in special …

Argatroban and bivalirudin are parenteral direct inhibitors of the activity of thrombin, but,
unlike heparin, can inhibit both soluble as well as clot-bound thrombin. These agents do not …